Cumberland Pharmaceuticals Net Income
| CPIX Stock | USD 3.86 0.11 2.93% |
As of the 3rd of February, Cumberland Pharmaceuticals shows the Mean Deviation of 4.47, downside deviation of 5.04, and Risk Adjusted Performance of 0.0584. Cumberland Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cumberland Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.2423 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -5.8 M | -5.5 M | |
| Net Loss | -5 M | -4.8 M | |
| Net Loss | -5.8 M | -5.5 M | |
| Net Loss | (0.53) | (0.50) | |
| Net Income Per E B T | 1.15 | 1.03 |
Cumberland | Net Income | Build AI portfolio with Cumberland Stock |
The evolution of Net Income for Cumberland Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Cumberland Pharmaceuticals compares to historical norms and industry peers.
Latest Cumberland Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Cumberland Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cumberland Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Cumberland Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cumberland Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cumberland Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (6.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cumberland Net Income Regression Statistics
| Arithmetic Mean | (2,439,255) | |
| Geometric Mean | 3,662,452 | |
| Coefficient Of Variation | (179.23) | |
| Mean Deviation | 3,604,145 | |
| Median | (3,507,587) | |
| Standard Deviation | 4,371,850 | |
| Sample Variance | 19.1T | |
| Range | 13.8M | |
| R-Value | (0.79) | |
| Mean Square Error | 7.6T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (686,843) | |
| Total Sum of Squares | 305.8T |
Cumberland Net Income History
Other Fundumenentals of Cumberland Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cumberland Pharmaceuticals Net Income component correlations
Cumberland Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cumberland Pharmaceuticals is extremely important. It helps to project a fair market value of Cumberland Stock properly, considering its historical fundamentals such as Net Income. Since Cumberland Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cumberland Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cumberland Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. Projected growth potential of Cumberland fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cumberland Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.24) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
Cumberland Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Cumberland's balance sheet. Smart investors calculate Cumberland Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Cumberland Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cumberland Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cumberland Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cumberland Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cumberland Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cumberland Pharmaceuticals.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Cumberland Pharmaceuticals on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Cumberland Pharmaceuticals or generate 0.0% return on investment in Cumberland Pharmaceuticals over 90 days. Cumberland Pharmaceuticals is related to or competes with Quantum BioPharma, Rockwell Medical, ABVC Biopharma, Lantern Pharma, Inotiv, CalciMedica Common, and Dyadic International. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commer... More
Cumberland Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cumberland Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cumberland Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.04 | |||
| Information Ratio | 0.0588 | |||
| Maximum Drawdown | 27.96 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 12.6 |
Cumberland Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cumberland Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cumberland Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Cumberland Pharmaceuticals historical prices to predict the future Cumberland Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0584 | |||
| Jensen Alpha | 0.3863 | |||
| Total Risk Alpha | 0.0228 | |||
| Sortino Ratio | 0.073 | |||
| Treynor Ratio | 0.6926 |
Cumberland Pharmaceuticals February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0584 | |||
| Market Risk Adjusted Performance | 0.7026 | |||
| Mean Deviation | 4.47 | |||
| Semi Deviation | 4.85 | |||
| Downside Deviation | 5.04 | |||
| Coefficient Of Variation | 1477.8 | |||
| Standard Deviation | 6.26 | |||
| Variance | 39.18 | |||
| Information Ratio | 0.0588 | |||
| Jensen Alpha | 0.3863 | |||
| Total Risk Alpha | 0.0228 | |||
| Sortino Ratio | 0.073 | |||
| Treynor Ratio | 0.6926 | |||
| Maximum Drawdown | 27.96 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 12.6 | |||
| Downside Variance | 25.36 | |||
| Semi Variance | 23.47 | |||
| Expected Short fall | (5.34) | |||
| Skewness | 0.9956 | |||
| Kurtosis | 1.85 |
Cumberland Pharmaceuticals Backtested Returns
Cumberland Pharmaceuticals is very risky given 3 months investment horizon. Cumberland Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of risk over the last 3 months. We were able to collect and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.02% are justified by taking the suggested risk. Use Cumberland Pharmaceuticals Mean Deviation of 4.47, risk adjusted performance of 0.0584, and Downside Deviation of 5.04 to evaluate company specific risk that cannot be diversified away. Cumberland Pharmaceuticals holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cumberland Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cumberland Pharmaceuticals is expected to be smaller as well. Use Cumberland Pharmaceuticals treynor ratio, as well as the relationship between the expected short fall and day median price , to analyze future returns on Cumberland Pharmaceuticals.
Auto-correlation | -0.51 |
Good reverse predictability
Cumberland Pharmaceuticals has good reverse predictability. Overlapping area represents the amount of predictability between Cumberland Pharmaceuticals time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cumberland Pharmaceuticals price movement. The serial correlation of -0.51 indicates that about 51.0% of current Cumberland Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.51 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cumberland Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cumberland Pharmaceuticals reported net income of (6.48 Million). This is 101.9% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 101.13% higher than that of the company.
Cumberland Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cumberland Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cumberland Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cumberland Pharmaceuticals by comparing valuation metrics of similar companies.Cumberland Pharmaceuticals is currently under evaluation in net income category among its peers.
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 44.7M | 69.6M | 25.6M | 33.3M | 38.3M | 36.4M | |
| Enterprise Value | 39.2M | 58.6M | 25.7M | 35.9M | 41.3M | 39.3M |
Cumberland Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cumberland Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cumberland Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Cumberland Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Cumberland Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cumberland Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cumberland Pharmaceuticals' value.| Shares | Blackrock Inc | 2025-06-30 | 51.2 K | State Street Corp | 2025-06-30 | 33.7 K | Heron Bay Capital Management | 2025-06-30 | 33.3 K | Two Sigma Investments Llc | 2025-06-30 | 32.3 K | Northern Trust Corp | 2025-06-30 | 19.6 K | Cresset Asset Management, Llc | 2025-06-30 | 19.5 K | Simplex Trading, Llc | 2025-06-30 | 14.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 12.4 K | Susquehanna International Group, Llp | 2025-06-30 | 11.5 K | Millennium Management Llc | 2025-06-30 | 776 K | Ikarian Capital, Llc | 2025-06-30 | 595.9 K |
Cumberland Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0286 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 50.38 M | ||||
| Shares Outstanding | 14.96 M | ||||
| Shares Owned By Insiders | 41.63 % | ||||
| Shares Owned By Institutions | 23.02 % | ||||
| Number Of Shares Shorted | 100.83 K | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 2.15 X | ||||
| Price To Sales | 1.40 X | ||||
| Revenue | 37.87 M | ||||
| Gross Profit | 34.88 M | ||||
| EBITDA | 182.42 K | ||||
| Net Income | (6.48 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 20.57 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.75 X | ||||
| Cash Flow From Operations | (612.19 K) | ||||
| Short Ratio | 0.35 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 91 | ||||
| Beta | -0.53 | ||||
| Market Capitalization | 57.75 M | ||||
| Total Asset | 75.58 M | ||||
| Retained Earnings | (23.97 M) | ||||
| Working Capital | 4.83 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
| Net Asset | 75.58 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.